Ipsen and Probi have reached an agreement covering 18 countries — primarily within the European Union and emerging markets — for the commercialization of Probi’s probiotic strain Lactobacillus plantarum 299v.
This clinically documented probiotic with patents in the gastro-intestinal field is expected to complement Ipsen’s strong medical portfolio in gastroenterology. For Probi, this could become one of the company's largest distribution agreements so far.
Under this new agreement, Probi will supply bulk LP299V capsules and Ipsen will be responsible for packaging, marketing and selling the product. To be marketed primarily through pharmacies, the product is expected to launch in the first half of 2017 as a food supplement in Europe, then in other key markets such as Russia and China, depending on regulatory approval.
The agreement covers in total 18 markets, many with high growth potential, with an option to include additional countries. The product will be marketed under Ipsen’s key brand and Probi’s trademark LP299V.
Marc de Garidel, chairman and chief executive officer of Ipsen said, “Ipsen is delighted to enter the field of probiotics with a very well-recognized and R&D focused company such as Probi. This partnership is fully aligned with our strategy to strengthen our portfolio in the field of gastroenterology and expand into probiotics.”
Probi Chief Executive Officer Peter Nählstedt said, “We have found a perfect match with Ipsen, a very well-respected pharmaceutical company with high growth ambitions and strong brands in the gastrointestinal field. Through its extensive organization, we expect to enter many new markets with LP299V, which will strengthen Probi´s footprint on the global market. We have high expectations and consider the agreement to have a high volume potential.”